Looking closerI would say that the FDA respone is a little like my alternative "B", i.e.more information/re-submitting.
So expect the stock to trade in the 4-8 cents range over the coming months until another dilutive financing hits the stock price. Maybe accelerated by a reversed split.
It was not a total refusal by FDA, they even suggest going through PMA.
There is still some hope ......